Xeris Biopharma Holdings, Inc. $XERS Stock: Profund Advisors LLC Grows Stake

Profund Advisors LLC increased its stake in shares of Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) by 519.2% during the third quarter, according to the company in its most recent filing with the SEC. The fund owned 202,547 shares of the company’s stock after acquiring an additional 169,836 shares during the period. Profund Advisors LLC’s holdings in Xeris Biopharma were worth $1,936,000 as of its most recent filing with the SEC.

A number of other institutional investors have also made changes to their positions in XERS. Allworth Financial LP lifted its holdings in Xeris Biopharma by 86.4% in the 2nd quarter. Allworth Financial LP now owns 4,315 shares of the company’s stock worth $34,000 after purchasing an additional 2,000 shares during the last quarter. China Universal Asset Management Co. Ltd. grew its holdings in Xeris Biopharma by 7.0% during the third quarter. China Universal Asset Management Co. Ltd. now owns 33,266 shares of the company’s stock valued at $332,000 after purchasing an additional 2,190 shares during the last quarter. AlphaCentric Advisors LLC grew its holdings in Xeris Biopharma by 5.7% during the first quarter. AlphaCentric Advisors LLC now owns 45,886 shares of the company’s stock valued at $266,000 after purchasing an additional 2,494 shares during the last quarter. GK Wealth Management LLC bought a new position in shares of Xeris Biopharma in the third quarter valued at approximately $32,000. Finally, VIRGINIA RETIREMENT SYSTEMS ET Al raised its position in shares of Xeris Biopharma by 30.1% in the third quarter. VIRGINIA RETIREMENT SYSTEMS ET Al now owns 14,700 shares of the company’s stock valued at $141,000 after purchasing an additional 3,400 shares during the period. 42.75% of the stock is owned by institutional investors.

Xeris Biopharma Price Performance

Shares of XERS stock opened at $10.71 on Monday. Xeris Biopharma Holdings, Inc. has a 12 month low of $5.25 and a 12 month high of $11.41. The firm has a market cap of $1.95 billion, a PE ratio of -97.36 and a beta of 0.53. The stock has a 50 day moving average of $9.31 and a 200-day moving average of $7.51. The company has a quick ratio of 1.02, a current ratio of 1.45 and a debt-to-equity ratio of 17.00.

Xeris Biopharma (NASDAQ:XERS) last announced its quarterly earnings data on Thursday, August 6th. The company reported ($0.18) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.01 by ($0.19). Xeris Biopharma had a positive return on equity of 338.21% and a negative net margin of 5.12%. The company had revenue of $92.10 million during the quarter, compared to analyst estimates of $90.12 million. On average, equities analysts predict that Xeris Biopharma Holdings, Inc. will post 0.07 EPS for the current year.

Insiders Place Their Bets

In other news, insider Kevin McCulloch sold 15,000 shares of the business’s stock in a transaction dated Thursday, October 1st. The shares were sold at an average price of $9.41, for a total transaction of $141,150.00. Following the transaction, the insider owned 1,599,208 shares in the company, valued at approximately $15,048,547.28. The trade was a 0.93% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Steven Pieper sold 5,000 shares of the company’s stock in a transaction dated Thursday, October 1st. The shares were sold at an average price of $9.41, for a total transaction of $47,050.00. Following the transaction, the insider directly owned 1,351,053 shares of the company’s stock, valued at $12,713,408.73. This represents a 0.37% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 103,332 shares of company stock worth $948,871 in the last ninety days. Insiders own 4.35% of the company’s stock.

Analyst Upgrades and Downgrades

Several research firms recently issued reports on XERS. Barclays upped their price objective on shares of Xeris Biopharma from $12.00 to $14.00 and gave the stock an “overweight” rating in a report on Tuesday, October 6th. Leerink Partners lifted their target price on shares of Xeris Biopharma from $12.00 to $16.00 and gave the stock an “outperform” rating in a report on Thursday, September 10th. Weiss Ratings lowered shares of Xeris Biopharma from a “hold (c-)” rating to a “sell (d-)” rating in a research report on Tuesday, August 11th. Finally, Wall Street Zen raised shares of Xeris Biopharma from a “hold” rating to a “buy” rating in a research report on Saturday, September 19th. Four investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, Xeris Biopharma presently has a consensus rating of “Moderate Buy” and a consensus target price of $13.20.

Xeris Biopharma Company Profile

Xeris Biopharma, Inc is a specialty pharmaceutical company focused on developing and commercializing therapies for patients with endocrinology, gastroenterology and other serious or chronic conditions. The company uses proprietary formulation and delivery technologies designed to make complex therapies more stable, convenient and suitable for self-administration.

Xeris’ commercial portfolio includes Gvoke, a ready-to-use glucagon injection for the treatment of severe hypoglycemia in adults and children with diabetes; Recorlev (levoketoconazole), an oral therapy for endogenous hypercortisolemia associated with endogenous Cushing’s syndrome; and Keveyis (dichlorphenamide), a treatment for primary periodic paralysis.